Is Basal Insulin Always the First Choice for Initiation of Insulin Therapy in Type 2 Diabetic Patients?

Key words

diabetes - insulin therapy - oral drugs

References

• 1 Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.  Diabetes Care. 2006;  29 1963-1972
• 2 Simons WR, Vinod HD, Gerber RA, Bolinder B. Does rapid transition to insulin therapy in subjects with newly diagnosed type 2 diabetes mellitus benefit glycaemic control and diabetes-related complications? A German population-based study.  Experimental and Clinical Endocrinology and Diabetes. 2006;  114 520-526
• 3 Bouma M, Dekker JH, de Sonnaville JJ, van der Does FE, de VH, Kriegsman DM, Kostense PJ, Heine RJ, van Eijk JT. How valid is fasting plasma glucose as a parameter of glycemic control in non-insulin-using patients with type 2 diabetes?.  Diabetes Care. 1999;  22 904-907
• 4 Bonora E, Calcaterra F, Lombardi S, Bonfante N, Formentini G, Bonadonna RC, Muggeo M. Plasma glucose levels throughout the day and HbA(1c) interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control.  Diabetes Care. 2001;  24 2023-2029
• 5 Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).  Diabetes Care. 2003;  26 881-885
• 6 Schreiber SA, Russmann A. Insulin glargine and educational intervention in patients with type 2 diabetes in clinical practice: Long-term improvement in glycaemic control without weight gain.  Experimental and Clinical Endocrinology and Diabetes. 2006;  114 41-42
• 7 Kann PH, Wascher T, Zackova V, Moeller J, Medding J, Szocs A, Mokan M, Mrevlje F, Regulski M. Starting insulin therapy in type 2 diabetes: Twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin Glargine plus glimepiride.  Experimental and Clinical Endocrinology and Diabetes. 2006;  114 527-532

Correspondence